Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | TPH1 | P17752 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.34 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3034325 | 0.82 | PPARG (0.51) | LMNAPTGDR2PPARGPPARDPPARA | |
| SCHEMBL13219226 | 0.81 | HDAC6 (0.43) | LMNA | |
| SCHEMBL13219224 | 0.81 | HDAC6 (0.43) | LMNAPTGDR2PPARGPPARDPPARA | |
| SCHEMBL13219232 | 0.80 | ADAMTS4 (0.47) | PTGDR2PPARGPPARDPPARAPKM | |
| SCHEMBL13219211 | 0.79 | TBXAS1 (0.42) | PTGDR2PPARGPPARDPPARAFFAR4 | |
| SCHEMBL13219225 | 0.79 | MAPT (0.41) | LMNAPPARGPPARDPPARAPKM | |
| SCHEMBL13219212 | 0.79 | PPARG (0.43) | LMNAPTGDR2PPARGPPARDPPARA | |
| SCHEMBL3029874 | 0.79 | PPARG (0.65) | PPARGPPARDPPARA | |
| SCHEMBL13219234 | 0.78 | FFAR1 (0.46) | PPARGPPARDPPARAFFAR4 | |
| SCHEMBL13219219 | 0.78 | PPARG (0.40) | PTGDR2PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367828-B2 | PPAR active compounds | PLEXXIKON INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367828-B2 | PPAR active compounds | PLEXXIKON INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210036-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARD, PPARA | LMNA 2137/4885PTGDR2 343/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.